Actinium Pharmaceuticals, Inc. (ATNM)
Automate Your Wheel Strategy on ATNM
With Tiblio's Option Bot, you can configure your own wheel strategy including ATNM - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ATNM
- Rev/Share 0.0
- Book/Share 0.8236
- PB 1.8212
- Debt/Equity 0.0558
- CurrentRatio 9.3468
- ROIC -0.7913
- MktCap 46793850.0
- FreeCF/Share -1.0666
- PFCF -1.4064
- PE -1.0282
- Debt/Assets 0.0209
- DivYield 0
- ROE -1.2957
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 3
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Kuehn Law Encourages Investors of Actinium Pharmaceuticals, Inc. to Contact Law Firm
Published: June 10, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , June 10, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Actinium Pharmaceuticals, Inc. (NYSE: ATNM) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Insiders at Actinium Pharmaceuticals caused the company to misrepresent or fail to disclose that (1) the Company's data from the Sierra Trial was unlikely to satisfy the FDA's guidelines for the acceptance and approval of Iomab-B BLA; (2) the additional analyses, including long-term follow-ups that purportedly demonstrated a trend towards improved Overall Survival that the Company provided to the …
Read More
Shareholders of Actinium Pharmaceuticals, Inc. (ATNM): Protect Your Rights Before May 27, 2025 - Contact Levi & Korsinsky
Published: May 27, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 27, 2025 / If you suffered a loss on your Actinium Pharmaceuticals, Inc. (NYSE:ATNM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/actinium-lawsuit-submission-form?prid=150393&wire=1&utm_campaign=21 or contact Joseph E. Levi, Esq.
Read More
Levi & Korsinsky Urges Actinium (ATNM) Shareholders to Act Before Lead Plaintiff Deadline May 27, 2025
Published: May 27, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 27, 2025 / If you suffered a loss on your Actinium Pharmaceuticals, Inc. (NYSE:ATNM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/actinium-lawsuit-submission-form?prid=150356&wire=1&utm_campaign=19 or contact Joseph E. Levi, Esq.
Read More
ATNM DEADLINE TODAY: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Actinium Pharmaceuticals, Inc. Investors to Secure Counsel Before Important May 27 Deadline in Securities Class Action - ATNM
Published: May 27, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 27, 2025 / Rosen Law Firm: WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) between October 31, 2022 and August 2, 2024, both dates inclusive (the "Class Period"), of the important May 27, 2025 lead plaintiff deadline. SO WHAT: If you purchased Actinium securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Read More
ATNM LAWSUIT ALERT: Levi & Korsinsky Notifies Actinium Pharmaceuticals, Inc. Investors - Lead Plaintiff Deadline May 27, 2025
Published: May 26, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 26, 2025 / If you suffered a loss on your Actinium Pharmaceuticals, Inc. (NYSE:ATNM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/actinium-lawsuit-submission-form?prid=150254&wire=1&utm_campaign=7 or contact Joseph E. Levi, Esq.
Read More
Lost Money on Actinium Pharmaceuticals, Inc. (ATNM)? Urged to Join Class Action Before May 27, 2025 - Contact Levi & Korsinsky
Published: May 26, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 26, 2025 / If you suffered a loss on your Actinium Pharmaceuticals, Inc. (NYSE:ATNM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/actinium-lawsuit-submission-form?prid=150240&wire=1&utm_campaign=22 or contact Joseph E. Levi, Esq.
Read More
ATNM Deadline: ATNM Investors with Losses in Excess of $100K Have Opportunity to Lead Actinium Pharmaceuticals, Inc. Securities Fraud Lawsuit
Published: May 26, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , May 26, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) between October 31, 2022 and August 2, 2024, both dates inclusive (the "Class Period"), of the important May 27, 2025 lead plaintiff deadline. So what: If you purchased Actinium securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Read More
Class Action Lawsuit Filed: Actinium Pharmaceuticals, Inc. (ATNM) - Join by May 27, 2025 - Contact Levi & Korsinsky
Published: May 26, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 26, 2025 / If you suffered a loss on your Actinium Pharmaceuticals, Inc. (NYSE:ATNM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/actinium-lawsuit-submission-form?prid=150203&wire=1&utm_campaign=8 or contact Joseph E. Levi, Esq.
Read More
FINAL REMINDER ATNM DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Actinium Pharmaceuticals, Inc. Investors to Participate in the Class Action Lawsuit
Published: May 26, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 26, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Actinium Pharmaceuticals, Inc. ("Actinium" or "the Company") (NYSE:ATNM) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Actinium securities between March 31, 2022 and August 2, 2024, both dates inclusive (the "Class Period").
Read More
Lost Money on Actinium Pharmaceuticals, Inc. (ATNM)? Contact Levi & Korsinsky to Join Class Action Before May 27, 2025
Published: May 25, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 25, 2025 / If you suffered a loss on your Actinium Pharmaceuticals, Inc. (NYSE:ATNM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/actinium-lawsuit-submission-form?prid=150179&wire=1&utm_campaign=20 or contact Joseph E. Levi, Esq.
Read More
ATNM DEADLINE NOTICE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Actinium Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 27 Deadline in Securities Class Action – ATNM
Published: May 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, May 25, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) between October 31, 2022 and August 2, 2024, both dates inclusive (the “Class Period”), of the important May 27, 2025 lead plaintiff deadline.
Read More
ATNM Deadline: Rosen Law Firm Urges Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
Published: May 23, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers of securities of Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) between October 31, 2022, and August 2, 2024. Actinium describes itself as a “late-stage biopharmaceutical company that develops targeted radiotherapies.” For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegation.
Read More
Class Action Filed Against Actinium Pharmaceuticals, Inc. (ATNM) Over Securities Violations - Contact Levi & Korsinsky Today
Published: May 23, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 23, 2025 / If you suffered a loss on your Actinium Pharmaceuticals, Inc. (NYSE:ATNM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/actinium-lawsuit-submission-form?prid=149907&wire=1&utm_campaign=29 or contact Joseph E. Levi, Esq.
Read More
Class Action Filed Against Actinium Pharmaceuticals, Inc. (ATNM) - May 27, 2025 Deadline to Join - Contact Levi & Korsinsky
Published: May 23, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , May 23, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company") (NYSE: ATNM) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Actinium investors who were adversely affected by alleged securities fraud between October 31, 2022 and August 2, 2024.
Read More
May 27, 2025 Deadline: Join Class Action Lawsuit Against Actinium Pharmaceuticals, Inc. (ATNM) - Contact Levi & Korsinsky
Published: May 23, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 23, 2025 / If you suffered a loss on your Actinium Pharmaceuticals, Inc. (NYSE:ATNM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/actinium-lawsuit-submission-form?prid=149872&wire=1&utm_campaign=6 or contact Joseph E. Levi, Esq.
Read More
Securities Fraud Class Action Filed Against Actinium Pharmaceuticals, Inc. (ATNM) – Levi & Korsinsky Reminds Investors of May 27, 2025
Published: May 22, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 22, 2025 / If you suffered a loss on your Actinium Pharmaceuticals, Inc. (NYSE:ATNM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/actinium-lawsuit-submission-form?prid=149837&wire=1&utm_campaign=27 or contact Joseph E. Levi, Esq.
Read More
ATNM ALERT: Levi & Korsinsky Files Securities Fraud Class Action Against Actinium Pharmaceuticals, Inc. - May 27, 2025 Deadline
Published: May 22, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 22, 2025 / If you suffered a loss on your Actinium Pharmaceuticals, Inc. (NYSE:ATNM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/actinium-lawsuit-submission-form?prid=149817&wire=1&utm_campaign=26 or contact Joseph E. Levi, Esq.
Read More
Shareholders that lost money on Actinium Pharmaceuticals, Inc. (ATNM) Urged to Join Class Action – Contact Levi & Korsinsky to Learn More
Published: May 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company") (NYSE: ATNM) of a class action securities lawsuit.
Read More
Investors Urged to Contact Levi & Korsinsky for Information Before May 27, 2025 - Actinium Pharmaceuticals, Inc. (ATNM)
Published: May 22, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 22, 2025 / If you suffered a loss on your Actinium Pharmaceuticals, Inc. (NYSE:ATNM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/actinium-lawsuit-submission-form?prid=149786&wire=1&utm_campaign=5 or contact Joseph E. Levi, Esq.
Read More
Lost Money on Actinium Pharmaceuticals, Inc. (ATNM)? Contact Levi & Korsinsky Before May 27, 2025 to Join Class Action
Published: May 22, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 22, 2025 / If you suffered a loss on your Actinium Pharmaceuticals, Inc. (NYSE:ATNM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/actinium-lawsuit-submission-form?prid=149767&wire=1&utm_campaign=12 or contact Joseph E. Levi, Esq.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATNM
Published: May 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Actinium Pharmaceuticals, Inc. (“Actinium” or the “Company”) (NYSE: ATNM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Read More
Lost Money on Actinium Pharmaceuticals, Inc. (ATNM)? Contact Levi & Korsinsky to Join Class Action Before May 27, 2025
Published: May 22, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 22, 2025 / If you suffered a loss on your Actinium Pharmaceuticals, Inc. (NYSE:ATNM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/actinium-lawsuit-submission-form?prid=149713&wire=1&utm_campaign=20 or contact Joseph E. Levi, Esq.
Read More
ATNM INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Investors of Actinium Pharmaceuticals, Inc. to Contact the Firm Today!
Published: May 22, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 22, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Actinium Pharmaceuticals, Inc. ("Actinium" or "the Company") (NYSE:ATNM) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Actinium securities between March 31, 2022 and August 2, 2024, both dates inclusive (the "Class Period").
Read More
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Lawsuit - ATNM
Published: May 22, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , May 22, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Actinium Pharmaceuticals, Inc. (NYSE: ATNM). Shareholders who purchased shares of ATNM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Read More
Class Action Filed Against Actinium Pharmaceuticals, Inc. (ATNM) Over Securities Violations - Contact Levi & Korsinsky Today
Published: May 22, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 22, 2025 / If you suffered a loss on your Actinium Pharmaceuticals, Inc. (NYSE:ATNM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/actinium-lawsuit-submission-form?prid=149698&wire=1&utm_campaign=29 or contact Joseph E. Levi, Esq.
Read More
Class Action Alert: Levi & Korsinsky Reminds Actinium (ATNM) Investors of May 27, 2025 Deadline
Published: May 21, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 21, 2025 / If you suffered a loss on your Actinium Pharmaceuticals, Inc. (NYSE:ATNM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/actinium-lawsuit-submission-form?prid=149680&wire=1&utm_campaign=17 or contact Joseph E. Levi, Esq.
Read More
Securities Lawsuit Alert: Actinium Pharmaceuticals, Inc. (ATNM) - Contact Levi & Korsinsky Before May 27, 2025
Published: May 21, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 21, 2025 / If you suffered a loss on your Actinium Pharmaceuticals, Inc. (NYSE:ATNM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/actinium-lawsuit-submission-form?prid=149660&wire=1&utm_campaign=3 or contact Joseph E. Levi, Esq.
Read More
Shareholders of Actinium Pharmaceuticals, Inc. (ATNM): Protect Your Rights Before May 27, 2025 Contact Levi & Korsinsky
Published: May 21, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 21, 2025 / If you suffered a loss on your Actinium Pharmaceuticals, Inc. (NYSE:ATNM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/actinium-lawsuit-submission-form?prid=149597&wire=1&utm_campaign=21 or contact Joseph E. Levi, Esq.
Read More
Class Action Alert: Levi & Korsinsky Reminds Actinium (ATNM) Investors of May 27, 2025 Deadline
Published: May 21, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 21, 2025 / If you suffered a loss on your Actinium Pharmaceuticals, Inc. (NYSE:ATNM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/actinium-lawsuit-submission-form?prid=149580&wire=1&utm_campaign=17 or contact Joseph E. Levi, Esq.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATNM
Published: May 21, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 21, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company") (NYSE:ATNM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
Read More
About Actinium Pharmaceuticals, Inc. (ATNM)
- IPO Date 2012-12-27
- Website https://www.actiniumpharma.com
- Industry Biotechnology
- CEO Mr. Sandesh C. Seth M.B.A., M.S.
- Employees 31